Ophthalmology: ozone therapy applied to dystrophic maculopathy

Giorgio Grechi

doi:10.4081/ozone.2017.6746

Ophthalmology: ozone therapy applied to dystrophic maculopathy

https://doi.org/10.4081/ozone.2017.6746

PDF HTML

Vol. 2 No. 1 (2017)

Submitted: 12 April 2017
Accepted: 3 May 2017

Published: 30 May 2017

Oxygen-ozone therapy, Ophthalmology, Dystrophic maculopathy

Abstract Views: 1187

PDF: 899
HTML: 877

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Giorgio Grechi
info@ossigenoozono.it
Oculist, Italy.

The macula, which is the noblest part of the retina, is a very small structure, containing the photoreceptors (rods and cones) responsible for visual acuity. Over the years, observations have confirmed that alterations that modify the optimal state of the eye also give rise to similar diseases in the brain: ischemias, structural circulatory alterations and neurodegeneration. As the body ages, oxidative alterations take place and they change the antioxidant systems that serves as a neurological and ocular defence. In industrialised nations, age-related macular degeneration is the leading cause of blindness in patients over 55 years of age. Initially, this creates drusen (or colloid cysts) in the macular area.